Levetiracetam Solution
Product Images NDC 70518-3804

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 70518-3804). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Remedy_label (Remedy Label)

Remedy_label (Remedy Label)
Label for Levetiracetam 100 mg/mL oral solution, packaged as 10 individual 10 mL cups. The label includes dosage strength (1000 mg/10 mL), dosage form (oral solution), quantity, and manufacturer information. It also displays a barcode, QR code, and repackager information for RemedyRepack Inc., with storage instructions and a caution to keep the medication out of reach of children.*
FDA Label Image

Mm2 (Levetiracetam 1000mg 10ml 70518 3804 01)

Mm2 (Levetiracetam 1000mg 10ml 70518 3804 01)
Levetiracetam 1000 mg/10 mL oral solution label showing the 10 mL quantity. The label includes the reminder to see package insert for directions, manufacturer information, and repackaging details by RemedyRepack Inc. The label also displays a barcode and a QR code.*
FDA Label Image

Figure 1: Responder Rate (≥50% Reduction From Baseline) In Study 1 (Levetiracetam Fig1)

Figure 1: Responder Rate (≥50% Reduction From Baseline) In Study 1 (Levetiracetam Fig1)
A bar chart titled 'Responder Rate (≥50% Reduction from Baseline) in Study 1' comparing the percentage of patients responding to placebo, Levetiracetam 1000 mg/day, and Levetiracetam 3000 mg/day. Percentages are approximately 7.4% for placebo, 37.1% for 1000 mg/day, and 39.6% for 3000 mg/day, with statistical significance noted for both Levetiracetam doses versus placebo.*
FDA Label Image

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (Levetiracetam Fig2)

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (Levetiracetam Fig2)
A bar chart titled 'Responder Rate (≥50% Reduction from Baseline) in Study 2: Period A' showing the percentage of patients responding to placebo and two doses of levetiracetam (1000 mg/day and 2000 mg/day). The chart highlights response rates of 6.3% for placebo, 20.8% for the 1000 mg/day dose, and 35.2% for the 2000 mg/day dose, with a note that responses marked by an asterisk are statistically significant versus placebo.*
FDA Label Image

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (Levetiracetam Fig3)

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (Levetiracetam Fig3)
A bar chart titled 'Responder Rate (≥50% Reduction from Baseline) in Study 3' comparing the percentage of patients responding to placebo versus Levetiracetam 3000 mg/day. The placebo group shows about 14.4% responder rate, while the Levetiracetam group shows about 39.4%, indicating a statistically significant difference.*
FDA Label Image

Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Levetiracetam Fig4)

Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Levetiracetam Fig4)
A bar graph titled 'Responder Rate (≥ 50% Reduction from Baseline) in Study 4' comparing placebo and Levetiracetam in terms of percent of patients. The placebo group (N=97) shows a responder rate of 19.6%, while the Levetiracetam group (N=101) shows a higher responder rate of 44.6%, marked as statistically significant versus placebo.*
FDA Label Image

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Levetiracetam Fig5)

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Levetiracetam Fig5)
A bar chart illustrating the responder rate for patients aged 1 month to less than 4 years in Study 5, showing the percentage of patients with at least 50% reduction from baseline. The chart compares placebo (19.6%) and Levetiracetam (43.1%), with Levetiracetam demonstrating a statistically significant higher responder rate versus placebo.*
FDA Label Image

Table 15: Median Percent Reduction From Baseline In Pgtc Seizure Frequency Per Week In Study 7 (Levetiracetam Fig6)

Table 15: Median Percent Reduction From Baseline In Pgtc Seizure Frequency Per Week In Study 7 (Levetiracetam Fig6)
A bar graph showing the responder rate defined as at least 50% reduction from baseline in PGTC seizure frequency per week in Study 7. The graph compares placebo (N=84) with a responder rate of 45.2% to Levetiracetam (N=79) with a responder rate of 72.2%, indicating statistical significance versus placebo.*
FDA Label Image

Chemical Structure (Levetiracetam Str)

Chemical Structure (Levetiracetam Str)
Chemical structure of Levetiracetam. The diagram shows the molecular structure with carbon, hydrogen, nitrogen, and oxygen atoms arranged to represent the active ingredient Levetiracetam.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.